Mesenchymal stem cells cancel azoxymethane-induced tumor initiation

Stem Cells

Volumn 32, Issue 4, 2014, Pages 913-925

  Nasuno, Masanao ^a   Arimura, Yoshiaki ^a   Nagaishi, Kanna ^a   Isshiki, Hiroyuki ^a   Onodera, Kei ^a   Nakagaki, Suguru ^a   Watanabe, Shuhei ^a   Idogawa, Masashi ^a   Yamashita, Kentaro ^a   Naishiro, Yasuyoshi ^a   Adachi, Yasushi ^a   Suzuki, Hiromu ^a   Fujimiya, Mineko ^a   Imai, Kohzoh ^b   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Azoxymethane; Chemoprevention; Colorectal cancer; Mesenchymal stem cells; Tumor initiation

Indexed keywords

6 O METHYLGUANINE; AZOXYMETHANE; DEXTRAN SULFATE; DNA METHYLTRANSFERASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CARCINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE; COLITIS; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA ADDUCT; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; INTESTINE EPITHELIUM CELL; MESENCHYMAL STEM CELL; NONHUMAN; RAT; TUMOR PROMOTION; WNT SIGNALING PATHWAY; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; COCULTURE; COLON TUMOR; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; HUMAN; LEWIS RAT; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; TOXICITY;

ANIMALS; AZOXYMETHANE; CARCINOGENS; CELLS, CULTURED; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED LEW; TRANSFORMING GROWTH FACTOR BETA; WNT SIGNALING PATHWAY;

EID: 84896336619     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1594     Document Type: Article

References (59)

1. Scadden DT,. Cancer stem cells refined. Nat Immunol 2004; 5: 701-703.
2. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
3. Sell S,. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51: 1-28.
4. Bhowmick NA, Neilson EG, Moses HL,. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-337.
5. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-851.
6. Orimo A, Gupta PB, Sgroi DC, et al. The influence of the microenvironment on the malignant phenotype. Mol Med Today 200; 6: 324-329.
7. Bissell MJ, Radisky D,. Putting tumours in context. Nature Rev Cancer 2001; 1: 46-54.
8. Dvorak HF,. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
9. Hall B, Andreeff M, Marini F,. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007; 180: 263-283.
10. Ruan J, Ji J, Song H, et al. Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer. Nanoscale Res Lett 2012; 7: 309.
11. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203: 1235-1247.
12. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-565.
13. Corpet DE, Pierre F,. How good are rodent models of carcinogenesis in predicting efficacy in humans A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 2005; 41: 1911-1922.
14. Neufert C, Becker C, Neurath MF,. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Prot 2007; 2: 1998-2004.
15. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
16. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
17. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
18. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-296.
19. Papanikolaou A, Shank RC, Delker DA, et al. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol Appl Pharmacol 1998; 150: 196-203.
20. Bissahoyo A, Pearsall RS, Hanlon K, et al. Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: Effects of dose, route, and diet. Toxicol Sci 2005; 88: 340-345.
21. Maltzman T, Whittington J, Driggers L, et al. AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 1997; 18: 2435-2439.
22. Takahashi M, Nakatsugi S, Sugimura T, et al. Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000; 21: 1117-1120.
23. Guillem JG, Hsieh LL, O'Toole KM, et al. Changes in expression of oncogenes and endogenous retroviral-like sequences during colon carcinogenesis. Cancer Res 1988; 48: 3964-3971.
24. Wang QS, Papanikolaou A, Sabourin CL, et al. Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Carcinogenesis 1998; 19: 2001-2006.
25. Vivona AA, Shpitz B, Medline A, et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 1993; 14: 1777-1781.
26. Yabana T, Arimura Y, Tanaka H, et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol 2009; 218: 350-359.
27. Tanaka H, Arimura Y, Yabana T, et al. Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat. J Gastroenterol 2011; 46: 143-152.
28. Hakamata Y, Tahara K, Uchida H, et al. Green fluorescent protein-transgenic rat: A tool for organ transplantation research. Biochem Biophys Res Commun 2001; 286: 779-785.
29. Javazon EH, Colter DC, Schwarz EJ, et al. Rat marrow stromal cells are more sensitive to plating density and expand more rapidly from single-cell-derived colonies than human marrow stromal cells. Stem Cells 2001; 19: 219-225.
30. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
31. Goldschneider I, Gordon LK, Morris RJ,. Demonstration of Thy-1 antigen on pluripotent hemopoietie stem cells in the rat. J Exp Med 1978; 1441: 1351-1366.
32. Kimura G, Itagaki A, Summers J,. Rat cell line 3y1 and its virogenic polyoma- and sv40-transformed derivatives. Int J Cancer 1975; 15: 694-706.
33. Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 965-973.
34. Bird RP,. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett 1987; 37: 147-151.
35. McLellan EA, Bird RP,. Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res 1988; 48: 6187-6192.
36. Sanger F, Nicklen S, Coulson AR,. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 12: 5463-5467.
37. Sladowski D, Steer SJ, Clothier RH, et al. An improved MTT assay. Immunol Methods 1993; 157: 203-207.
38. Sasaki T, Yoshida K, Shimura H, et al. Inhibitory effect of linoleic acid on transformation of IEC6 intestinal cells by in vitro azoxymethane treatment. Int J Cancer 2006; 118: 593-599.
39. Tabachnick BG, Fidell LS,. Using Multivariate Statistics, Fifth Edition. Boston, MA: Pearson Education Inc., 2007: 1-1008.
40. Hu Y, Martin J, Leu RL, et al. The colonic response to genotoxic carcinogens in the rat: Regulation by dietary fibre. Carcinogenesis 2002; 23: 1131-1137.
41. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339: 1277-1284.
42. Caderni G, Femia AP, Giannini A, et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: Correlation with carcinogenesis. Cancer Res 2003; 63: 2388-2392.
43. Le Leu RK, Brown IL, Hu Y, et al. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. J Nutr 2005; 135: 996-1001.
44. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97: 1330-1338.
45. Sohn OS, Fiala ES, Requeijo SP, et al. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res 2001; 61: 8435-8440.
46. Quiros S, Roos WP, Kaina B,. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010; 9: 168-178.
47. Borinstein SC, Conerly M, Dzieciatkowski S, et al. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol Carcinog 2010; 49: 94-103.
48. Kitange GJ, Mladek AC, Carlson BL, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 2012; 18: 4070-4079.
49. Kreth S, Limbeck E, Hinske LC, et al. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 2013; 125: 671-681.
50. Labbé E, Lock L, Letamendia A, et al. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res 2007; 67: 75-84.
51. Derynck R, Akhurst RJ, Balmain A,. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
52. Guda K, Claffey KP, Dong M, et al. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog 2003; 37: 51-59.
53. Guda K, Giardina C, Nambiar P, et al. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors. Mol Carcinog 2001; 31: 204-213.
54. Wang QS, Guda K, Papanikolaou A, et al. Expression of transforming growth factor-beta1 and its type II receptor in mouse colon tumors induced by azoxymethane. Int J Oncol 2000; 17: 551-558.
55. Bird RP, Good CK,. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000; 112-113: 395-402.
56. Thorup I,. Histomorphological and immunohistochemical characterization of colonic aberrant crypt foci in rats: Relationship to growth factor expression. Carcinogenesis 1997; 18: 465-472.
57. Shao J, Sheng H, Aramandla R, et al,. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication error positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999; 20: 185-191.
58. Chen J, Huang XF,. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009; 8: 1313-1317.
59. Meulmeester E, ten Dijke P,. The dynamic roles of TGF-β in cancer. J Pathol 2011; 223: 205-218.